- Home
- SRFM vs ARMP Comparison
SRFM vs ARMP Comparison
Compare SRFM & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | ARMP |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.7M | 125.7M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRFM | ARMP |
|---|---|---|
| Price | $2.19 | $6.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.81 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 5.4M | 54.2K |
| Earning Date | 03-17-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $108,158,000.00 | $5,054,000.00 |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | $8.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.77 | $0.90 |
| 52 Week High | $9.91 | $16.34 |
Technical Indicators
Market Signals| Indicator | SRFM | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 50.58 |
| Support Level | $2.13 | $5.75 |
| Resistance Level | $2.69 | $6.37 |
| Average True Range (ATR) | 0.25 | 0.74 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 4.74 | 29.26 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.